Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 6, 2008, Pages 1386-1391

  Hachem, R Y ^a   Langston, A A ^b   Graybill, J R ^c   Perfect, J R ^d   Pedicone, L D ^e   Patino, H ^e   Raad, I I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antifungals; Aspergillosis; Azoles; Refractory IFIs

Indexed keywords

AMPHOTERICIN B; CREATININE; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FOSCARNET; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; VORICONAZOLE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPERGILLOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME BLOOD LEVEL; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; PHASE 3 CLINICAL TRIAL; QT PROLONGATION; SALVAGE THERAPY; SIDE EFFECT; VOMITING;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 56649089881     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn401     Document Type: Article

References (35)

1. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32 358-66.
2. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56 Suppl 1: I5-11.
3. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: The SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
4. Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management. Blood 1997; 90 999-1008.
5. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
6. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49 Suppl 1: 37-41.
7. Trotman RL, Williamson JC, Shoemaker DM et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005; 41: 1159-66.
8. Keating GM. Posaconazole. Drugs 2005; 11: 1553-67.
9. Sabatelli F, Patel R, Mann PA et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-15.
10. Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44: 2-12.
11. Imai JK, Singh G, Clemons KV et al. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004; 48: 4063-6.
12. Imai JK, Singh G, Clemons KV et al. Efficacy of posaconazole in a murine model of central nervous system aspergillosis [erratum]. Antimicrob Agents Chemother 2004; 48: 4931.
13. Petraitiene R, Petraitis V, Groll AH et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45: 857-69.
14. Najvar LK, Cacciapuoti A, Hernandez S et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: Comparative studies in two laboratories. Antimicrob Agents Chemother 2004; 48: 758-64.
15. Kirkpatrick WR, McAtee RK, Fothergill AW et al. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 780-2.
16. Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1504-7.
17. Krieter P, Flannery B, Musick T et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48: 3543-51.
18. Courtney R, Sansone A, Smith W et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005; 45: 185-92.
19. Raad I, Chapman S, Bradsher R et al. Posaconazole (POS) salvage therapy for invasive fungal infections (IFI). In: Abstracts of the Forty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2004. Abstract M-669, p. 412. American Society for Microbiology, Washington, DC, USA.
20. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clin Infect Dis 2002; 34: 7-14.
21. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard M27-A. NCCLS, Wayne, PA, USA, 1997.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
23. Sansone-Parsons A, Krishna G, Calzetta A et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50: 1881-3.
24. Raad II, Graybill JR, Bustamante AB et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42: 1726-34.
25. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance. Clin Pharmacokinet 2000; 38: 111-80.
26. Saeki T, Ueda K, Tanigawara Y et al. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268: 6077-80.
27. Wexler D, Courtney R, Richards W et al. Effect of posaconazole on cytochrome P450 enzymes: A randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21: 645-53.
28. Floren LC, Bekersky I, Benet LZ et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997; 62: 41-9.
29. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: Drug interactions of clinical significance. Drug Saf 1998; 18: 83-97.
30. Furlan V, Parquin F, Penaud JF et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant Proc 1998; 30: 187-8.
31. Shitrit D, Ollech JE, Ollech A et al. Itraconazole prophylaxis in lung transplant recipients receiving tacrolimus (FK 506): Efficacy and drug interaction. J Heart Lung Transplant 2005; 24: 2148-52.
32. Osowski CL, Dix SP, Lin LS et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996; 61: 1268-72.
33. Romero AJ, Pogamp PL, Nilsson LG et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71: 226-34.
34. Sansone-Parsons A, Krishna G, Martinho M et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 27: 825-34.
35. Schering Corporation. 2006. NOXAFIL® (posaconazole) oral suspension.